Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 31Observational 4Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Myeloid, Chronic-Phase 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 446Surgical Procedures, Operative 164Observation 152Drug Therapy 142Radiotherapy 141Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 78Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 66Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 61Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 46

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × asciminib × Clear all
NCT05943522 2026-04-20

Asciminib RMP Study

Novartis

Recruiting
600 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06092879 2026-02-06

ASSURE-3

Novartis

Active not recruiting
201 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07091019 2025-07-29

ASC4REAL-2

Novartis

Not yet recruiting
1,000 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

NCT05421091 2024-03-27

Special Drug Use-results Surveillance of Scemblix Tablets

Novartis

Completed
550 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡